Abstract: The present invention relates to the application of a platelet gel for augmenting or restoring the volume of a soft tissue, particularly breast tissue, to biological implants comprising said gel, to a kit for preparing said implants and to a process for preparing said implants.

Abstract: The present invention relates to a method for obtaining a tissue engineering product designed to regenerate cartilage tissue, said product comprising expanded bone marrow mesenchymal cells, a non-cellular matrix and a fibrin gel, the method comprising the steps of: (a) expanding the mesenchymal cells; (b) conjugating the mesenchymal cells to the matrix; (c) washing the product obtained in step (b); and (d) mixing the product obtained in step (c) with a fibrin gel.

Abstract: The present invention relates to the application of a platelet gel for augmenting or restoring the volume of a soft tissue, particularly breast tissue, to biological implants comprising said gel, to a kit for preparing said implants and to a process for preparing said implants.

Abstract: The present invention relates to a method for obtaining connective mesenchymal stem cells from the mononuclear fraction of human bone marrow cells using type AB human serum as a supplement. Said method includes the steps of obtaining said mononuclear fraction of bone marrow, the step of recovering and pre-expanding the connective stem cells and the step of expanding the connective stem cells until obtaining the clinical dose required for the therapeutic use thereof.

Abstract: Procedure for the undifferentiated or myeloid lineage biased expansion of haematopoietic stem cells coming from umbilical cord blood, mobilized peripheral blood or bone marrow. Procedure for the undifferentiated or myeloid lineage biased expansion of haematopoietic stem cells (HSCs). More specifically, the present invention relates to a procedure of expansion of HSCs from umbilical cord blood, bone marrow or mobilized peripheral blood. Said procedure comprises the steps of expansion culturing of the purified CD34+ cells at constant volume, expansion culturing of said cells at variable volume and the conditioning of the CD34+ cells for transplantation. With this procedure the dose of undifferentiated or myeloid lineage biased HSCs which is necessary for their clinical use is produced reproducibly, robustly and safely.

Abstract: Method and kit based on real-time PCR with specific primers and probes that allow to achieve a high degree of subtyping of the complete HLA-B locus. The main advantages are the greater speed (65 minutes, including the interpretation); the ease of automation, since only eighteen tubes are necessary to obtain a good level of resolution (typing of 300 groups); reduction of the total cost per test thanks to the ease of automation and the simplicity; a surprisingly high degree of allele definition is achieved; and the risk of sample contamination is reduced because the amplified products always remain in the tubes and no post-PCR steps are necessary.